Loading clinical trials...
Loading clinical trials...
A Safety and Efficacy Study of Intratumoral Diffusing Alpha Radiation Emitters in Recurrent Unresectable or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Interventions
Diffusing Alpha Radiation Emitters Therapy (DaRT)
Pembrolizumab
Locations
3
Israel
Sharett institute, Hadassah University Hospital - Ein-Kerem
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Tel-Aviv Medical Center
Tel Aviv, Israel
Start Date
November 2, 2021
Primary Completion Date
December 1, 2026
Completion Date
June 1, 2027
Last Updated
April 6, 2026
NCT06532279
NCT05005403
NCT06163534
NCT06980038
NCT05039801
NCT05702398
Lead Sponsor
Alpha Tau Medical LTD.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions